Reversible thrombotic aortic valve restenosis after valve-in-valve transcatheter aortic valve replacement

Catheter Cardiovasc Interv. 2018 Jan 1;91(1):165-168. doi: 10.1002/ccd.26522. Epub 2016 May 14.

Abstract

Thrombotic aortic valve restenosis following transcatheter aortic valve replacement (TAVR) has not been extensively reported and the rates of TAVR valve thrombosis are not known. We present three cases of valve-in-valve (VIV) restenosis following TAVR with the balloon expandable transcatheter heart valves, presumably due to valve thrombosis that improved with anticoagulation. © 2016 Wiley Periodicals, Inc.

Keywords: anticoagulants/antithrombins; antiplatelet therapy; aortic valve disease; percutaneous intervention; percutaneous valve therapy; structural heart disease intervention; transcatheter valve implantation.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Aged, 80 and over
  • Anticoagulants / therapeutic use
  • Aortic Valve Stenosis / diagnostic imaging
  • Aortic Valve Stenosis / physiopathology
  • Aortic Valve Stenosis / surgery*
  • Balloon Valvuloplasty / adverse effects
  • Echocardiography, Doppler
  • Echocardiography, Transesophageal
  • Heart Valve Prosthesis Implantation / adverse effects*
  • Heart Valve Prosthesis Implantation / instrumentation
  • Humans
  • Male
  • Middle Aged
  • Recurrence
  • Reoperation
  • Thrombosis / diagnostic imaging
  • Thrombosis / drug therapy
  • Thrombosis / etiology*
  • Thrombosis / physiopathology
  • Transcatheter Aortic Valve Replacement / adverse effects*
  • Treatment Outcome

Substances

  • Anticoagulants